Endocyte (ECYT) reported quarterly earnings results on Wednesday, May-4-2016. The company said it had a profit of $-0.24 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.25. During the same quarter in the previous year, the company posted $-0.26 EPS.
Many Wall Street Analysts have commented on Endocyte. Shares were Reiterated by Wedbush on Mar 3, 2016 to “Outperform” and Lowered the Price Target to $ 8 from a previous price target of $12 .
Endocyte (ECYT) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $3.89 and reached the intraday high at $3.95. The bulls started the profit booking and pushed the shares to intraday low of $3.75. The trading session was marked by a volume range of 1,50,925 shares exchanging hands. The 52-week high of the shares is $6.35 and the 52-week low is $2.65. The market cap of the company stands at $164 M and there are 4,21,52,733 shares in public circulation.
In a different news, on Jan 20, 2016, Fred A Middleton (director) purchased 30,000 shares at $2.80 per share price. According to the SEC, on Mar 5, 2015, Binh Nguyen (VP of Medical Affairs) sold 29,883 shares at $5.79 per share price.
Endocyte Inc. (Endocyte) is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. The Company’s pipeline includes: Vintafolide (Vynfinit or EC145) which delivers potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor expressed on cancer cells but not on most normal cells; Folate-Tubulysin (EC1456) an SMDC (small molecule drug conjugates) consisting of folate (vitamin B9) linked to a potent cytotoxic agent tubulysin B hydrazide (TubBH); EC0652 a prostate-specific membrane antigen (PSMA)-targeted molecular imaging agent; EC1169 an investigational injectable PSMA-targeted SMDC; Etarfolatide (Folcepri or EC20) a folate-targeted molecular imaging agent; EC1669 a new approach to inflammation therapy targeting an anti-folate drug to activated macrophages expressing folate receptors; EC0371 a folate-targeted water-soluble form of rapamycin and EC1788 a Folate-targeted SMDC.